Santhera Pharmaceuticals (SIX: SANN) says its bid to broaden the European label of Raxone (idebenone) has been delayed.
The Swiss drugmaker has applied to extend the marketable use of the drug, to include slowing loss of respiratory function in patients with Duchenne muscular dystrophy (DMD) who are currently not taking glucocorticoids.
Santhera says it is “now expecting to receive a request for supplementary information to further support the clinical relevance of our data,” and anticipates a decision in the third quarter of this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze